Latham Advises on Northern Oil and Gas’s US$500 Million Private Senior Notes Offering

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

Andersen Group Inc. announced a secondary offering of 4.28 million shares of Class A common stock at $44 per share, with gross proceeds of $188.5 million for selling stockholders. The offering is expected to close on August 21, 2026, with underwriters having a 30-day option to purchase additional shares. Andersen is not selling shares and will not receive proceeds. Latham & Watkins LLP represents the underwriters.

Latham Group (SWIM) secured $375 million in new credit facilities, including a $75 million revolving credit line and a $300 million term loan, led by Jefferies Finance. The facilities will refinance and extend the company's maturities, replacing a 2022 Barclays-led agreement. The revolver matures in 2031, and the term loan in 2033.

Northern Oil and Gas (NYSE:NOG) priced a $500M offering of 7.5% senior notes due 2034. Proceeds will repay borrowings and fund general corporate purposes. The offering is for qualified institutional buyers under Rule 144A or non-U.S. persons under Regulation S.